Exact Sciences
EXAS
#1795
Rank
S$12.26 B
Marketcap
$66.29
Share price
-3.14%
Change (1 day)
-25.62%
Change (1 year)
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.

Revenue for Exact Sciences (EXAS)

Revenue in 2024 (TTM): S$3.52 Billion

According to Exact Sciences's latest financial reports the company's current revenue (TTM ) is S$3.51 Billion. In 2023 the company made a revenue of S$3.30 Billion an increase over the revenue in the year 2022 that were of S$2.79 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exact Sciences from 2001 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) S$3.52 B6.66%
2023 S$3.30 B18.15%
2022 S$2.79 B16.96%
2021 S$2.38 B21.08%
2020 S$1.97 B67.01%
2019 S$1.18 B90.28%
2018 S$0.62 B74.52%
2017 S$0.35 B147.35%
2016 S$0.14 B157.82%
2015 S$55.78 M2248.07%
2014 S$2.37 M-54.75%
2013 S$5.25 M3.6%
2012 S$5.06 M-6%
2011 S$5.39 M-21.68%
2010 S$6.88 M3.05%
2009 S$6.67 M
2007 S$4.22 M-42.01%
2006 S$7.28 M2.93%
2005 S$7.07 M-12.11%
2004 S$8.05 M63.35%
2003 S$4.92 M216.67%
2002 S$1.55 M1552.71%
2001 S$0.09 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
S$1.07 B-69.29%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.24 B-92.96%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.53 B-84.70%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$4.62 Million-100.13%๐Ÿ‡บ๐Ÿ‡ธ USA
S$71.90 B 1,948.50%๐Ÿ‡ซ๐Ÿ‡ท France